NEw test 

http://genoteqhealthcare.com/admin/conferencesession/new

Dementia is not a normal part of aging. It is a disease. Nearly 48 million people living with dementia and dementia related diseases throughout the world.  About 5% of people between the ages of 65–74 have dementia, 20% between 75 and 84 and nearly half of those over 85 years of age. The total estimated worldwide cost of dementia is nearly US$900 billion in 2018. By 2020, the global cost of dementia will rise above a US$1.5 trillion. Dementia is caused when the brain is damaged by diseases, such as Alzheimer’s disease or a series of strokes. It becomes more common with age. Many diseases can cause dementia, including Alzheimer's disease, vascular dementia, Lewy Body disease, head trauma, fronto-temporal dementia, Parkinson’s disease, and Huntington’s disease etc.

The most common type of dementia is Alzheimer's disease, which makes up 50% to 70% of cases. Memory problems are typically one of the first signs of Alzheimer’s, though initial symptoms may vary from person to person. Mild cognitive impairment (MCI) is a condition that can be an early sign of Alzheimer’s.

This session covers the topics on Causes, Subcortical dementia, Cerebral amyloid angiopathy, stroke, Diabetes, risk factors, symptoms, diagnosis, clinical trials, care practice etc of vascular dementia.

According to recent studies, people who have sustained a traumatic brain injury have a higher risk of developing dementia and Alzheimer’s disease. More research is needed to find what happens during a TBI and how severe brain injury leads to dementia, what other factors play a role etc.

Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia. Currently there is no cure for Alzheimer disease. Early diagnosis may leads to reduced deaths caused by Alzheimer’s. In this particular track we are able to discuss on Neurofibrillary tangle, MRI, Amyloid beta, Tau, Cognitive impairment, preclinical studies, Pathophysiology, Pharmacological studies etc.

Neuroimaging play a vital role in diagnosis, disease staging, and, most importantly, development of effective disease-modifying therapies in Alzheimer disease. There are several in-vitro, In-vivo techniques are used to understand Alzheimer disease which includes: PET, MRI, SPECT, VBM, fMRI etc. Few topics included in this session, Role of imaging techniques in the diagnosis of dementia& Alzheimer’s, advanced neuroimaging techniques, Brain imaging in Alzheimer &dementia, Neuro radiology.

Caring for older people with multiple health problems can be tricky, even for healthcare professionals who specialize in GERIATRICS, the medical care of older adults. Behavioural symptoms in patients with neurodegenerative diseases can be particularly challenging for caregivers. Recent studies show that, most of the physicians were unaware of cognitive impairment in more than 40 percent of their cognitively impaired patients.

As the disease progresses, an Alzheimer’s disease patient will become increasingly dependent upon his or her caregivers. Behavioural and mood disorders, common in individuals with Alzheimer’s disease, are the most disturbing aspect of the disease for many caregivers. These disorders include depression, agitation, wandering, and sleep disturbances. Care giving is an important component of the management of AD. The role of the caregiver changes over time as the needs of the person with AD change.

Current Alzheimer’s treatments only increase performance of chemicals in the brain, but don’t stop the death of brain cells. There are number of clinical and preclinical studies required to diagnose and cure the disease. Few topics are to be discussed in this session, Research on new drug targets in alzheimers and dementia, Dementia risk reduction and prevention research, Pharmacological studies, Clinical trials, Non medication treatments, Non medication treatments etc.

Amyloid-beta (Aβ) plays a key role in the pathogenesis of Alzheimer’s disease. Amyloid is a general term for protein fragments that the body produces normally. In a healthy brain, these protein fragments are broken down and eliminated. In Alzheimer's disease, the fragments accumulate to form hard, insoluble plaques.

Clinical trials are research studies play a important role to determine whether treatments are safe and effective. Without clinical trials there is no treatment and no cure for Alzheimer disease. This session mainly focussed on Latest trend and innovations in clinical trials, Treatment trials, Diagnostic studies, Prevention trails etc.

Alzheimer's disease is a neurodegenerative disorder with unclear etiology for a few decades. Many animal models employed to study the etiology of the disease and test the efficacy of drugs.This session may incorporates, Current Animal Models of Alzheimer’s disease, Research for better animal models of Alzheimer’s disease, Current concepts and new trends.

In 2017, there are nearly 960 million people aged 60 or over in the world. This will be increased to 2 billion in 2050. As the population grows older, age-related diseases such as dementia and Alzheimer’s will increases. The greatest challenge facing us as we age is the prevention of physical disability and the extension of "active life expectancy." Human societies will need to develop mechanisms and social practices in the future to minimise or mitigate social detachment. This session includes, Neurodegenerative diseases, HIV links with Dementia, advance research in ageing and dementia, Epidemiology, Prevention etc.

Various Pharmacological options are presently available for the symptomatic treatment of Alzheimer disease. These treatments provide mild but sustained benefits. Current pharmacological therapy for Alzheimer’s dementia is very limited and primarily aims at achieving symptom control. Under diagnosis and under treatment of AD are significant problems in the present clinical approach to the disorder. Early diagnosis and comprehensive management of cognitive and behavioural symptoms are crucial in optimizing disease management.